Patient-Reported Outcome (PRO) Consortium

Research Areas

- Tool Development
- Data-Sharing Enabler

At a Glance

- Status: Completed Consortium
- Year Launched: 2009
- Initiating Organization: C-Path
- Initiator Type: Nonprofit foundation
- Location: North America

Abstract

The Patient-Reported Outcome (PRO) Consortium aims to develop qualified and publicly available PRO instruments for use in clinical trials in order to support labeling claims. The consortium focuses on developing, evaluating, and qualifying PRO instruments for use as primary or secondary endpoint measures in clinical trials designed to evaluate treatment benefit.

Mission

The Patient-Reported Outcome (PRO) Consortium brings together scientists from C-Path, industry, academia, and regulatory agencies in a pre-competitive environment for the purpose of developing, evaluating, and qualifying PRO instruments for use as primary or secondary endpoint measures in clinical trials designed to evaluate treatment benefit. A patient-reported outcome is any report of the status of a patient’s health condition that comes directly from the patient, without interpretation of the patient’s response by a clinician or anyone else. Well-defined and reliable PRO instruments can be used to support a claim in medical product labeling if the claim is consistent with the instrument’s documented measurement capability. PRO-based endpoints currently used in clinical trials and incorporated in labeling usually are disease-specific. However, there are multiple PRO tools to measure the same concept (e.g., asthma symptom severity). For some indications, reliable PRO
instruments have not been developed. The lack of standardized, fit-for-purpose PRO tools that are
qualified for regulatory use has led to inefficiencies in drug development and review processes. Also,
this may result in inconsistencies in the types of outcome information contained in the labeling for
drugs approved for the same indication.

The main objectives of the PRO Consortium are to develop, evaluate, and qualify PRO instruments
with the U.S. Food and Drug Administration (FDA) for use in clinical trials designed to evaluate the
safety and effectiveness of medical products. Specific milestones include:

**Consortium History**

2008 – The consortium was formed
2009 – The consortium formally launched

**Structure & Governance**

The PRO Consortium’s members are pharmaceutical companies along with C-Path. Representatives
from the FDA, EMA, and the U.S. National Institutes of Health provide advice to the PRO
Consortium’s Coordinating Committee. The PRO Consortium Team is as follows:

**Financing**

The working groups for the project are mainly funded by industry.

**Data Sharing**

PRO instruments will be publicly available.

Nine working groups have been established in the following therapeutic areas: asthma, functional
dyspepsia, irritable bowel syndrome, major depressive disorder, mild cognitive impairment due to
Alzheimer’s disease, multiple sclerosis, myelofibrosis, non-small cell lung cancer, and rheumatoid arthritis.

The following PRO measures have been developed and are undergoing quantitative testing prior to submission to the FDA for qualification for use in exploratory studies:

- Asthma Daily Symptoms Diary (ADSD)
- Diary of Irritable Bowel Syndrome Symptoms—Constipation (DIBSS-C)
- Diary of Irritable Bowel Syndrome Symptoms—Diarrhea (DIBSS-D)
- Diary of Irritable Bowel Syndrome Symptoms—Mixed (DIBSS-M)
- Functional Dyspepsia Symptom Diary (FDSD)
- Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ)
- Symptoms of Major Depressive Disorder Scale (SMDDS)

Homepage: [http://c-path.org/programs/pro/](http://c-path.org/programs/pro/)
Other website: [http://www.fda.gov/AboutFDA/PartnershipsCollaborations/PublicPrivatePartnershipProgram/ucm231129.htm](http://www.fda.gov/AboutFDA/PartnershipsCollaborations/PublicPrivatePartnershipProgram/ucm231129.htm)

**Points of Contact**

Stephen Joel Coons, PhD, PRO Consortium Executive Director
Critical Path Institute
Tucson, AZ
sjcoons@c-path.org

**Sponsors & Partners**

- European Medicines Agency
- Food and Drug Administration
- National Institutes of Health
- AbbVie
- ACTELION
- Allergan
- Amgen
- AstraZeneca
- Bayer